Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 9004 results

  1. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

  2. Ravulizumab for treating primary IgA nephropathy [ID6703]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

  3. MolecuLight i:X for wound imaging

    Topic prioritisation

  4. Intradiscal Platelet Rich Plasma (PRP) Injections for Back Pain with Modic Type 1 Changes

    Topic prioritisation

  5. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia

    Topic prioritisation

  6. LIVERFASt for diagnosing and staging liver injury and chronic liver disease, (MT783)

    Topic prioritisation

  7. RespiraSense (MT736)

    Topic prioritisation

  8. The Stak for knee stretching following knee replacement or injury or to treat osteoarthritis

    Topic prioritisation

  9. Aflibercept for untreated retinopathy in babies born preterm TS ID 11943

    Topic prioritisation

  10. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]

    Topic prioritisation

  11. Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy

    In development Reference number: GID-HTE10086 Expected publication date:  15 September 2026

  12. Ianalumab for treating active Sjogren's syndrome [ID6634]

    Awaiting development Reference number: GID-TA11836 Expected publication date: TBC

  13. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

  14. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

  15. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]

    Awaiting development Reference number: GID-TA11874 Expected publication date: TBC